Over the past decade, India has significantly expanded its role in global pharmaceutical outsourcing. What was once largely a generics-focused manufacturing hub has evolved into a diverse Contract Development and Manufacturing Organization (CDMO) ecosystem capable of supporting advanced drug development and manufacturing.
Indian CDMOs now provide services across complex small-molecule APIs, high-potency compounds, peptide synthesis, biologics manufacturing, and sterile injectable production. These capabilities have made the country an attractive partner for global pharmaceutical and biotechnology companies seeking reliable, scalable, and regulatory-compliant manufacturing.
As drug pipelines grow more specialized and development costs increase, pharmaceutical companies are shifting from transactional outsourcing models toward long-term strategic CDMO partnerships. The Indian CDMO market is expected to grow at an estimated 14–15% CAGR, with projections suggesting the sector could reach USD 18–19 billion by 2030 as companies diversify global supply chains.
Evaluation Criteria
To ensure an objective and balanced overview, the companies featured in this list were assessed based on several industry-relevant parameters:
- Years of operational experience
- International client base and partnerships
- Regulatory certifications and compliance track record
- Scope of service offerings (APIs, biologics, formulations)
- Manufacturing infrastructure and production scale
- Global presence and operational footprint
Leading CDMO Companies in India
(*Companies are listed in no particular order and not ranked.)
|
Company |
Founded | Headquarters | Core Services |
Key Strengths |
| Neuland Laboratories |
1984 |
Hyderabad |
Custom APIs, generic APIs, peptides |
Strong expertise in complex chemistry and peptide synthesis; pure-play API manufacturer |
| Divi’s Laboratories |
1990 |
Hyderabad |
Custom synthesis, APIs |
Large-scale manufacturing capabilities and long-term innovator partnerships |
| Jubilant Pharmova |
1978 |
Noida |
CRDMO services, sterile injectables |
Global CDMO network and sterile fill-finish expertise |
|
Syngene International |
1993 |
Bengaluru |
APIs, biologics, oligonucleotides |
Integrated discovery-to-commercial capabilities |
| Laurus Labs |
2005 |
Hyderabad |
APIs, formulations |
Advanced flow chemistry and biocatalysis technologies |
| MSN Laboratories |
2003 |
Hyderabad |
APIs, finished dosage forms |
Strong oncology pipeline and backward integration |
| Sai Life Sciences |
1999 |
Hyderabad |
CRDMO services |
Integrated discovery and manufacturing programs |
| Piramal Pharma Solutions |
1988 |
Mumbai |
HPAPIs, ADCs, sterile injectables |
Specialty drug modalities and global manufacturing sites |
| Hetero Labs |
1993 |
Hyderabad |
APIs, formulations |
Extensive generics portfolio and regulatory approvals |
| Aarti Drugs |
1984 |
Mumbai |
APIs, intermediates |
Multi-chemistry expertise and supply-chain integration |
Company Profiles
1. Neuland Laboratories Ltd
Founded: 1984
Headquarters: Hyderabad, Telangana
Overview:
Neuland Laboratories focuses on the development and manufacturing of complex small-molecule APIs and peptide-based therapeutics. The company supports pharmaceutical programs across the full development lifecycle—from early-stage research to commercial-scale manufacturing.
Key Capabilities
- End-to-end API development from laboratory research to commercial production
- Specialized expertise in complex chemistry and niche molecules
- Dedicated API manufacturing focus
- Three US FDA and cGMP-compliant facilities
- Total reactor capacity exceeding 1,100 KL
- Efficient scale-up capabilities ranging from gram-scale development to multi-ton production
2. Divi’s Laboratories
Founded: 1990
Headquarters: Hyderabad, Telangana
Overview:
Divi’s Laboratories is recognized for its custom synthesis and large-scale manufacturing of generic APIs and high-potency compounds.
Key Strengths
- Extensive large-scale production infrastructure
- Strategic capacity expansions, including facilities in Kakinada
- Long-standing collaborations with global pharmaceutical innovators
3. Jubilant Pharmova Ltd
Founded: 1978
Headquarters: Noida, Uttar Pradesh
Overview:
Jubilant Pharmova delivers integrated CRDMO and CDMO services spanning early discovery, API development, and sterile injectable manufacturing.
Key Strengths
- Comprehensive development-to-commercial manufacturing services
- Advanced sterile manufacturing and fill-finish capabilities
- Operational presence across India, North America, and Europe
4. Syngene International
Founded: 1993
Headquarters: Bengaluru, Karnataka
Overview:
Syngene provides integrated research, development, and manufacturing solutions covering both small molecules and biologics.
Key Strengths
- SynVent platform for accelerated drug discovery and preclinical development
- Large global client base across pharma and biotech sectors
- Strong ESG practices and governance standards
5. Laurus Labs
Founded: 2005
Headquarters: Hyderabad, Telangana
Overview:
Laurus Labs offers API manufacturing, formulation development, and contract manufacturing services for pharmaceutical companies worldwide.
Key Strengths
- Expertise in advanced flow chemistry and enzymatic biocatalysis
- Continuous investment in research and development infrastructure
- Strong compliance with global regulatory frameworks
6. MSN Laboratories
Founded: 2003
Headquarters: Hyderabad, Telangana
Overview:
MSN Laboratories focuses on API and finished dosage manufacturing while providing CRAMS/CDMO services for pharmaceutical partners.
Key Strengths
- Large-scale manufacturing infrastructure
- Integrated supply chain through backward integration
- Strong pipeline focused on oncology therapeutics
7. Sai Life Sciences
Founded: 1999
Headquarters: Hyderabad, Telangana
Overview:
Sai Life Sciences delivers contract research and manufacturing services covering discovery chemistry, process development, and commercial-scale manufacturing.
Key Strengths
- Major investments in Genome Valley research infrastructure
- Dual-location R&D capabilities
- Integrated discovery-to-commercial manufacturing model
8. Piramal Pharma Solutions
Founded: 1988
Headquarters: Mumbai, Maharashtra
Overview:
Piramal Pharma Solutions provides CDMO services for complex drug modalities including HPAPIs, antibody-drug conjugates (ADCs), and sterile injectable products.
Key Strengths
- End-to-end drug development and manufacturing capabilities
- Specialized expertise in complex therapeutic modalities
- Global manufacturing network spanning North America, Europe, and Asia
9. Hetero Labs
Founded: 1993
Headquarters: Hyderabad, Telangana
Overview:
Hetero Labs is a major pharmaceutical manufacturer providing APIs, formulations, and contract manufacturing services to global markets.
Key Strengths
- Extensive global generics portfolio
- Multiple regulatory approvals in regulated markets
- Strong vertically integrated manufacturing capabilities
10. Aarti Drugs
Founded: 1984
Headquarters: Mumbai, Maharashtra
Overview:
Aarti Drugs manufactures APIs, intermediates, and specialty pharmaceutical products while offering custom manufacturing services.
Key Strengths
- Expertise across multiple chemical synthesis processes
- Multi-product production facilities
- Strong supply-chain integration
Industry Outlook
India’s CDMO industry is expected to maintain steady growth over the coming decade as global pharmaceutical companies increasingly rely on outsourcing partners.
Several trends are shaping the sector’s evolution:
- Expansion in peptide and oligonucleotide manufacturing
- Rising demand for antibody-drug conjugates (ADCs) and biologics outsourcing
- Adoption of digital manufacturing technologies and single-use production systems
To remain competitive globally, leading Indian CDMOs are continuing to expand their international presence while investing in automation, sustainability initiatives, and advanced manufacturing technologies.
Why India is Becoming a Global CDMO Destination
India’s emergence as a CDMO hub is supported by several structural advantages:
1. Regulatory-approved manufacturing infrastructure:
India hosts more than 350 US FDA-registered pharmaceutical manufacturing facilities, one of the largest concentrations outside Western markets.
2. Cost-effective production:
Pharmaceutical manufacturing in India can be 30–40% more cost-efficient compared to facilities in North America or Europe.
3. Large scientific workforce:
The country produces over 200,000 life sciences graduates each year, providing a strong talent base for R&D and manufacturing operations.
4. Strong regulatory and IP frameworks:
Indian CDMOs operate under stringent quality systems aligned with international regulatory standards.
5. Rapid scalability:
Investments in modular facilities and single-use technologies allow CDMOs to quickly scale production for complex drug modalities such as peptides and oligonucleotides.
Together, these advantages make India a preferred outsourcing destination for pharmaceutical and biotechnology companies worldwide.
Conclusion:
India’s CDMO sector is playing an increasingly important role in global pharmaceutical manufacturing. With capabilities spanning complex APIs, biologics, and advanced therapeutic modalities, Indian CDMOs enable pharmaceutical companies to accelerate innovation while maintaining cost efficiency.
As the outsourcing landscape continues to evolve, selecting the right CDMO partner in India will remain a critical strategic decision for companies seeking long-term development and manufacturing support.
